Treatment of Advanced Melanoma in 2020 and Beyond
Top Cited Papers
- 31 December 2020
- journal article
- review article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 141 (1), 23-31
- https://doi.org/10.1016/j.jid.2020.03.943
Abstract
No abstract availableFunding Information
- National Cancer Institute (1K08CA226391)
- Melanoma Research Alliance
- Cancer Research Foundation
- V Foundation
- NIH
This publication has 93 references indexed in Scilit:
- Chemotherapy in the management of advanced cutaneous malignant melanomaClinics in Dermatology, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- KIT as a Therapeutic Target in Metastatic MelanomaJama-Journal Of The American Medical Association, 2011
- Staging and Prognosis of Cutaneous MelanomaSurgical Oncology Clinics of North America, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Mutations of the BRAF gene in human cancerNature, 2002